HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100CompaniesDeal TrackerResearch
Pharma

Daiichi Sankyo Company, Limited

1
Articles
Partner
Top Role
Apr 11, 2026
First Mention
Apr 11, 2026
Last Mention
1.25
Relevance Score

Coverage Timeline

April 2026
Keytruda’s $25B Question: Merck’s Playbook as Patent Expiry Nears Money Partner
Apr 11, 2026
Merck paid Daiichi Sankyo $4 billion upfront, chasing three ADCs (up to $22 billion in biobucks).
Related Companies
Prometheus Biosciences, Inc.
1 shared
Harpoon Therapeutics, Inc.
1 shared
Merck & Co., Inc.
1 shared
AbbVie Inc.
1 shared